Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 700 from DKK 900 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Trump’s Executive Order on Healthcare Aims to Lower Drug Costs for Americans
- Novo Nordisk initiated with an Underperform at BNP Paribas Exane
- Eli Lilly (LLY) Stock Jumps as Rival Pfizer Drops Out of Race to Develop Weight Loss Pill
- Novo Nordisk warns of counterfeit Ozempic injections
- Novo Nordisk warns consumers about counterfeit Ozempic injections